Myeloma: Drugs
(asked on 14th October 2020) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when assessment he has made of the timescale for the approval of lenalidomide as a maintenance drug for post stem cell transplant treatment of Myeloma.
This question was answered on 22nd October 2020
The National Institute for Health and Care Excellence (NICE) is currently developing guidance on lenalidomide for the maintenance treatment of multiple myeloma after autologous stem cell transplantation.
NICE expects to publish final guidance on lenalidomide in January 2021.